Intravenous thrombolysis for acute ischemic stroke: The Malabar experience 2003 to 2008

Journal of Clinical Neuroscience

Volumn 16, Issue 10, 2009, Pages 1276-1278

  Salam, K A ^a   Ummer, K ^a   Pradeep Kumar, V G ^a   Noone, M L ^a   Laila, A ^a   Ragini, J ^a  

^a Baby Memorial Hospital ^*  (India)

Author keywords

Cerebral infarction; India; Stroke; Thrombolytic therapy; Tissue plasminogen activator

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GINGIVA BLEEDING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANKIN SCALE; TREATMENT OUTCOME;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INDIA; INJECTIONS, INTRAVENOUS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 68949187954     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2009.01.004     Document Type: Article

References (15)

1. The World Health Report 1999. Geneva: World Health Organization, 1999;102.
2. Bonita R. Epidemiology of stroke. Lancet 339 (1992) 342-344
3. Hankey G., and Warlow C.P. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 354 (1999) 1457-1463
4. Warlow C. Epidemiology of stroke. Lancet 352 Suppl. 3 (1998) 1-4
5. Bamford J., Sandercock P., Dennis M., et al. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 53 (1990) 16-22
6. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
7. Practice advisory: thrombolytic therapy for acute ischemic stroke - summary statement. Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 47 (1996) 835-839
8. Padma M.V., Singh M.B., Bhatia R., et al. Hyperacute thrombolysis with IV rt-PA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. Neurol India 55 (2007) 46-49
9. Adams Jr. H.P., Bendixen B.H., Kappelle L.J., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 (1993) 35-41
10. Pfefferkorn T., Liebetrau M., Müllner A., et al. Increasing use of intravenous rt-PA does not affect safety in acute stroke. J Neurol 252 (2005) 1500-1503
11. Wahlgren N., Ahmed N., Dávalos A., et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369 (2007) 275-282
12. Litwin T., Kobayashi A., Skowrońska M., et al. Thrombolysis in acute ischaemic stroke within 3 hours of symptom onset: a report of the first 100 cases. Neurol Neurochir Pol 42 (2008) 1-5
13. Yoneda Y., Yamanot S., Hera Y., et al. Post-licensed 1-year experience of systemic thrombolysis with tissue plasminogen activator for ischemic stroke in a Japanese neuro-unit. Clin Neurol Neurosurg 109 (2007) 567-570
14. Trouillas P., Nighoghossian N., Derex L., et al. Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic, and radiological outcome factors. Stroke 29 (1998) 2529-2540
15. Albers G.W., Bates V.E., Clark W.M., et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283 (2000) 1145-1150